Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Deciphera Pharmaceuticals (DCPH) is a biotechnology innovator advancing targeted therapies for cancer through its expertise in kinase inhibition. This page provides investors and industry professionals with verified updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including quarterly earnings reports, FDA filings, clinical trial data, and partnership agreements. Our curated collection ensures you stay informed about DCPH's progress in developing small molecule therapeutics, particularly following its integration with Ono Pharmaceutical's global oncology network.
Key updates cover research breakthroughs, pipeline advancements, and operational developments within the company's Boston and Kansas research hubs. Bookmark this page for direct access to primary source materials and objective analysis of Deciphera's position in the competitive oncology therapeutics landscape.
Deciphera Pharmaceuticals (DCPH) announced the hiring of Lisa Amaya Price as Senior VP and Chief HR Officer. As part of her employment agreement, a stock option of 100,000 shares and 25,000 restricted stock units (RSUs) were granted. The options have a 10-year term at an exercise price of $16.64, the fair market value on the grant date of August 15, 2022. The options vest over four years, and the RSUs vest annually over three years. This grant was made under the Company’s 2022 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
Deciphera Pharmaceuticals announced the publication of Phase 3 results for QINLOCK® (ripretinib) in the Journal of Clinical Oncology, focusing on patients with advanced gastrointestinal stromal tumors (GIST) previously treated with imatinib. QINLOCK demonstrated comparable efficacy to sunitinib but did not meet the primary endpoint of superior progression-free survival (PFS). However, it exhibited a more favorable safety profile, with fewer Grade 3/4 adverse events and better patient-reported outcomes. The international study involved 453 patients, highlighting QINLOCK's potential in GIST treatment.
Deciphera Pharmaceuticals reported $32.5 million in total revenue for Q2 2022, with a 43% increase in net product revenue from QINLOCK, totaling $31.5 million. The company received recognition in Germany for QINLOCK as the first orphan oncology treatment to earn a 'major additional benefit' rating. Upcoming milestones include presentations at the ESMO Congress 2022, ongoing trials for vimseltinib, and a new development candidate expected by Q4 2022. The net loss for the quarter was $43.1 million, less than the previous year.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will report its second quarter 2022 financial results on August 4, 2022, at 8:00 AM ET. A conference call and webcast will follow to discuss the financial outcome and provide updates on corporate developments. Investors can access the live webcast through the company’s website, and a replay will be available later. Deciphera is focused on innovative cancer medicines, notably the switch control inhibitor QINLOCK®, approved in several regions including the US and Europe.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced the hiring of Kelley Dealhoy as Senior Vice President and Chief Business Officer. In connection with her employment, the Board's Compensation Committee approved stock options for 100,000 shares and 45,000 restricted stock units (RSUs) under the 2022 Inducement Plan. The options have a ten-year term with an exercise price of $13.01, vesting over four years. Deciphera specializes in cancer treatments and has developed QINLOCK®, approved in multiple countries for fourth-line GIST treatment.
Deciphera Pharmaceuticals has appointed Kelley Dealhoy as Senior Vice President and Chief Business Officer. With over 20 years in life sciences, she aims to enhance business development and corporate strategy. Kelley previously held key positions at Novartis, where she focused on business development in the oncology sector. CEO Steve Hoerter expressed enthusiasm for her extensive experience in strategic partnerships, which is critical as the company seeks to solidify QINLOCK®'s global market presence and advance its development pipeline. Kelley holds a Bachelor's in Biochemistry from Queen's University in Canada.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will participate in fireside chats at two investor conferences: Jefferies Healthcare Conference on June 9, 2022, and JMP Securities Life Sciences Conference on June 15, 2022. Both events will take place in New York, NY, starting at 10:00 AM ET. A live webcast will be available on the company's investor website and will be archived for 90 days. Deciphera focuses on developing medicines for cancer, including its approved product QINLOCK.
Deciphera Pharmaceuticals reported $29.2 million in total revenue for Q1 2022, with $28.8 million from QINLOCK net product sales. The company completed a public offering generating net proceeds of $163.4 million, ensuring funding through 2025. The Phase 3 MOTION study for vimseltinib in TGCT patients is underway, and promising preclinical data for DCC-3116 in combination with KRASG12C inhibitors was presented. Despite a net loss of $46.9 million for the quarter, the company maintains strong cash reserves of $275.4 million.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) will report its first quarter 2022 financial results on May 4, 2022. A live conference call and webcast are scheduled for 8:00 AM ET on the same day, where the management will discuss financial outcomes and company updates. Investors can access the call via a provided phone number or through a webcast available on the company's website. Deciphera focuses on developing innovative cancer therapies, including QINLOCK, which is approved in multiple regions including the U.S. and Europe.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has completed its public offering of 7,501,239 common stock shares and pre-funded warrants for 9,748,761 shares at $10.00 and $9.99, respectively. The offering generated approximately $172.5 million in gross proceeds. The funds will support ongoing clinical trials for vimseltinib and DCC-3116, including a pivotal Phase 3 study in tenosynovial giant cell tumor patients, as well as further research and development initiatives. J.P. Morgan and Jefferies acted as joint book-running managers for this offering.
FAQ
What is the current stock price of Deciphera Pharma (DCPH)?
What is the market cap of Deciphera Pharma (DCPH)?
